Blood test may tailor lung cancer immunotherapy, sparing unnecessary treatment
NCT ID NCT07759492
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial is testing whether a blood test that detects cancer DNA can guide the use of durvalumab, an immunotherapy, after standard chemoradiotherapy in patients with stage III lung cancer that cannot be removed by surgery. The goal is to see if giving durvalumab only to patients with detectable cancer DNA improves outcomes and avoids overtreating others. Participants will be divided based on the blood test result, with some receiving durvalumab and others not, to compare progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab, an immunotherapy drug, given after chemoradiotherapy, with treatment duration guided by a blood test for cancer DNA (ctDNA).
- What this could lead to
- If successful, this approach could personalize immunotherapy, giving it only to those who need it, reducing side effects and healthcare costs.
- What could go wrong
- The trial is in Phase 2, so results are preliminary. The ctDNA test may not accurately predict who benefits, and durvalumab can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE III UNRESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Angers - CHU
Paris, 75009, France
-
Avignon - Institut du Cancer Avignon-Provence
Paris, 75009, France
-
Bordeaux - CHU
Paris, 75009, France
-
Bordeaux - Polyclinique
Paris, 75009, France
-
Boulogne - APHP Ambroise Paré
Paris, 75009, France
-
Brest - CHU
Paris, 75009, France
-
Caen - CHU
Paris, 75009, France
-
Chambéry - CH
Paris, 75009, France
-
Clermont-Ferrand - CHU
Paris, 75009, France
-
Colmar - CH
Paris, 75009, France
-
Grenoble - CHU
Paris, 75009, France
-
La Roche-Sur-Yon - CHD Vendée
Paris, 75009, France
-
Le Mans - CHG
Paris, 75009, France
-
Lille - Centre Oscar Lambret
Paris, 75009, France
-
Limoges - CHU
Paris, 75009, France
-
Lyon - HCL
Paris, 75009, France
-
Marseille - APHM Nord
Paris, 75009, France
-
Marseille - Institut Paoli-Calmettes
Paris, 75009, France
-
Montpellier - CHU
Paris, 75009, France
-
Morlaix - CH
Paris, 75009, France
-
Nantes - Institut de Cancérologie de l'Ouest
Paris, 75009, France
-
Paris - APHP Bichat
Paris, 75009, France
-
Paris - APHP Cochin
Paris, 75009, France
-
Paris - APHP Pitié-Salpêtrière
Paris, 75009, France
-
Paris - APHP Tenon
Paris, 75009, France
-
Paris - Saint Joseph
Paris, 75009, France
-
Poitiers - CHU
Paris, 75009, France
-
Reims - Institut Godinot
Paris, 75009, France
-
Toulon - Sainte Anne HIA
Paris, 75009, France
-
Tours - CHU
Paris, 75009, France
-
Vannes - Bretagne Atlantique
Paris, 75009, France
-
Villefranche sur Saône - CH
Paris, 75009, France